FierceBiotech 15 avr. 2026 FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
FierceBiotech 14 avr. 2026 Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
FierceBiotech 14 avr. 2026 Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
FierceBiotech 14 avr. 2026 Cell therapy biotech Obsidian leverages Galera reverse merger to go public
FierceBiotech 14 avr. 2026 Harbinger Health raises $100M for new suite of blood-based cancer detection tests
FierceBiotech 14 avr. 2026 Alamar Biosciences files for IPO amid opening life sciences funding window
FierceBiotech 14 avr. 2026 Boehringer, Amgen discard early immunology candidates over lack of clinical potential
FierceBiotech 13 avr. 2026 Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets
FierceBiotech 13 avr. 2026 Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
FierceBiotech 13 avr. 2026 AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
FierceBiotech 13 avr. 2026 Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
FierceBiotech 13 avr. 2026 BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech 13 avr. 2026 Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
FierceBiotech 13 avr. 2026 Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates